Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001

Clinical Infectious Diseases

Volumn 38, Issue 9, 2004, Pages 1251-1256

  Bergman, Miika ^a,e   Huikko, Solja ^a,b   Pihlajamäki, Marja ^a   Laippala, Pekka ^b,c   Palva, Erkki ^d   Huovinen, Pentti ^a   Seppälä, Helena ^a  

^a TURKU CITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d National Agency of Medicines   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG USE; FINLAND; HUMAN; LABORATORY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PYOGENES; DRUG UTILIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PRESCRIPTION; STREPTOCOCCUS INFECTION;

DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ERYTHROMYCIN; FINLAND; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; PRESCRIPTIONS, DRUG; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 2342504476     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/383309     Document Type: Article

References (24)

1. World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. Geneva, Switzerland: WHO, 2001.
2. Seppälä H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of erythromycin: link to increased erythromycin resistance in group A streptococci. Clin Infect Dis 1995; 21:1378-85.
3. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337:441-6.
4. Granizo JJ, Aguilar L, Casal J, Dal-Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000; 46:959-64.
5. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal-Re R, Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46:767-73.
6. Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva E, Huovinen P. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001; 33:483-8.
7. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 2002; 40:2959-63.
8. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8:278-82.
9. Garcia-Rey C, Aguilar L, Baquero F, Casal J, Dal-Re R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40:159-64.
10. Cižman M. The use and resistance to antibiotics in the community. Int J Antimicrob Agents 2003; 21:297-307.
11. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200-6.
12. Alos JI, Aracil B, Oteo J, Gomez-Garces JL. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. J Antimicrob Chemother 2003; 51:333-7.
13. Dicuonzo G, Fiscarelli E, Gherardi G, et al. Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy. Antimicrob Agents Chemother 2002; 46:3987-90.
14. Hoban D, Waites K, Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis 2003; 45:251-9.
15. Petinaki E, Kontos F, Pratti A, Skulakis C, Maniatis AN. Clinical isolates of macrolide-resistant Streptococcus pyogenes in central Greece. Int J Antimicrob Agents 2003; 21:67-70.
16. Reinert RR, Lutticken R, Bryskier A, Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 2003; 47:489-93.
17. Sauermann R, Gattringer R, Graninger W, Buxbaum A, Georgopoulos A. Phenotypes of macrolide resistance of group A streptococci isolated from outpatients in Bavaria and susceptibility to 16 antibiotics. J Antimicrob Chemother 2003; 51:53-7.
18. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49:61-8.
19. National Agency for Medicines and the Social Insurance Institution. Finnish statistics on medicines 1995-2001. Helsinki: National Agency for Medicines and the Social Insurance Institution, 2002.
20. NCCLS. Performance standards for antimicrobial disc susceptibility tests. 6th ed. Wayne, PA: NCCLS, 1997.
21. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11(Suppl 1):35-43.
22. Baquero F. Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study. J Antimicrob Chemother 1996; 38(Suppl A):117-32.
23. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96:1152-6.
24. Rautakorpi UM, Klaukka T, Honkanen P, et al. Antibiotic use by indication: a basis for active antibiotic policy in the community. Scand J Infect Dis 2001; 33:920-6.